Roivant Sciences Ltd. (ROIV)

Over the past six months, Roivant Sciences Ltd.'s stock price has increased substantially. Positive Phase 3 data for brepocitinib in dermatomyositis was announced, with an NDA filing anticipated in the first half of calendar year 2026. Roivant completed a $1.5 billion share repurchase program and approved a new $500 million program. QVT Financial LP significantly reduced its holdings in Roivant Sciences Ltd. Insider selling activity occurred. Roivant reported consolidated cash, cash equivalents, restricted cash, and marketable securities of approximately $4.5 billion as of June 30, 2025, and $4.4 billion as of September 30, 2025.

There is no specific information indicating demand seasonality for Roivant Sciences Ltd.'s products and services. Its revenue streams are often tied to clinical trial progress, regulatory approvals, and partnership agreements rather than seasonal consumer demand for commercialized products.

Roivant Sciences Ltd. is a multinational healthcare company applying technology to drug development and creating subsidiary life sciences and health technology companies. It operates in the Pharmaceuticals sector and Biotechnology industry, generating revenue through collaboration agreements, licensing fees, milestone payments, and product revenue. Key pipeline assets include Brepocitinib for conditions like dermatomyositis, IMVT-1402 (and batoclimab) for autoimmune diseases, and Vtama for psoriasis and atopic dermatitis. Roivant has over a dozen subsidiaries, including Immunovant, Priovant, Dermavant Sciences, and Lokavant.

Roivant Sciences Ltd. is headquartered in New York City, U.S., with major offices in Boston, U.S., and Basel, Switzerland. The company was initially incorporated in Bermuda.

Information specifically detailing Roivant Sciences Ltd.'s brand reputation or events that have affected it in the past year is not readily available. The available information primarily focuses on financial performance, drug development milestones, and corporate actions.

Roivant Sciences Ltd. is owned by a mix of institutional shareholders, insiders, and retail investors. Approximately 72.10% of the company is owned by institutional shareholders, including Fmr Llc, Morgan Stanley, and BlackRock, Inc. Insiders own approximately 97.87% of the company. Qvt Financial LP is the largest individual shareholder, and Vivek Ramaswamy, the founder, owns approximately 7.03% of the common stock.